| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4030200 | Ophthalmology | 2007 | 6 Pages |
Abstract
Acute myelogenous leukemia is a rare secondary malignancy among retinoblastoma patients, many of whom were treated with primary or adjuvant chemotherapy. Additional studies are needed to assess potential risk factors contributing to sAML development in this cohort.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Dan S. MD, FACS, John FRCS, David H. MD, FACS, Judith MBChB, FRCP, Guillermo MD, Ira J. MD, Celia B.G. MD, PhD, Mark MD, Barret G. MD, FACS, Carlos A. MD, Aurora MD, Amy C. MD, Gavivann MD, Regina MD, Norbert MD, Mathew W. MD, FACS,